Objective:To confirm the improvement of cardiac function and quality of life (QoL) in patients with chronic heart failure (CHF) via Chinese medicine (CM) Qishen Taohong Granule (QTG).Methods:This study was a single-center,prospective,randomized,controlled clinical trial.Seventy-six patients from 27 to 84 years old diagnosed with CHF New York Heart Association (NYHA) class Ⅱ or Ⅲ in stage C were enrolled and randomly assigned at a 1∶1 ratio to receive QTG or trimetazidine (TMZ),in addition to their standard medications for the treatment of CHF.The study period was 4 weeks.The primary outcomes included cardiac function evaluated by NYHA classification and left ventricular ejection fraction (LVEF),as well as QoL evaluated by CHF Integrated Chinese and Western Medicine Survival Scale (CHFQLS).The secondary outcomes included 6-min walking test (6MWT),CM syndrome score,symptom and sign scores and N-terminal pro-B-type natriuretic peptide level (NT-proBNP).All indices were measured at baseline and the end of the trial.Results:At the 4-week follow-up period,the effective rate according to NYHA classification in the QTG group was better than that in the TMZ group (74.29％ vs.54.29％,P＜0.05).But there was no significant difference in post-treatment level of LVEF between the two groups (P＞0.05).The CHFQLS scores improved by 13.82 ± 6.04 vs.7.49± 2.28 in the QTG and TMZ groups,respectively (P＜0.05).Subgroup analysis of the CHFQLS results showed that physiological function,role limitation and vitality were significantly higher in the QTG group than in the TMZ group (15.76±7.85 vs.7.40±3.36,P＜0.05;16.00±8.35 vs.10.53±4.64,P＜0.05;15.31 ±8.09 vs.7.89± 4.60,P＜0.05).Compared with TMZ group,treatment with QTG also demonstrated superior performance with respect to 6MWT,CM syndrome,shortness of breath,fatigue,gasping,general edema and NT-proBNP level.No significant adverse reactions or adverse cardiac events occurred during treatment in either group.Conclusion:In addition to conventional treatments,the use of QTG as an adjuvant therapy significantly improved cardiac function and QoL in patients with CHF class Ⅱ or Ⅲ in stage C.[Registration No.ChiCTR1900022036 (retrospectively registered)]